SugarHarmony Consumer Concerns Under Investigation: Critiquing The Sugar Harmony Claims




SugarHarmony Consumer Concerns Under Investigation: Critiquing The Sugar Harmony Claims

An informational 2026 consumer evaluation examining common SugarHarmony search queries, ingredient transparency concerns, marketing claim context, refund and fulfillment policy requirements, and what verification steps consumers should complete before purchasing Sugar Harmony Drops

Tallmadge, OH, March 04, 2026 (GLOBE NEWSWIRE) — Where this report uses terms such as “critiquing” or “investigating,” it refers to a neutral review of publicly available marketing statements and policies as published by the company — not an opinion, endorsement, or performance judgment. All details should be verified on the official website.

This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, terms such as “results,” “support,” or “effectiveness” refer strictly to how Sugar Harmony Drops marketing materials describe potential outcomes. These terms do not indicate that Sugar Harmony Drops has been clinically proven effective as a finished proprietary formula.

Search activity around Sugar Harmony Drops has generated a pattern of consumer questions in early 2026 that go well beyond basic product information. Queries such as “is SugarHarmony legitimate,” “Sugar Harmony complaints,” “Sugar Harmony Drops side effects,” and similar intent terms reflect consumers trying to verify product information beyond promotional summaries. This report addresses those concern categories using only publicly available company documentation and ingredient-level research context.

This report evaluates what the company states, what its published policies require, and what ingredient-level research may suggest in general — without implying clinical proof for the finished product. It does not recommend for or against purchasing Sugar Harmony Drops.

Evidence standard used in this report: (1) company-published pages including the product page, refund policy, shipping policy, and terms of service; (2) ingredient-level peer-reviewed research where cited by the company; and (3) consumer verification steps that can be completed prior to purchase. Ingredient studies referenced below do not establish clinical proof of the finished Sugar Harmony Drops formula.

Current product details, pricing, and terms can be confirmed by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen, particularly if you are currently managing an existing health condition or taking prescription medications.

What Consumer Concerns Around Sugar Harmony Drops Look Like in 2026

Consumer concern patterns in the supplement category tend to cluster around ingredient transparency, evidence type, refund requirements, fulfillment procedures, and brand accountability. Sugar Harmony Drops generates search queries across all five of those categories. Rather than addressing them with generic reassurances, this evaluation examines each concern against what the company’s own published materials actually state — and what they leave unaddressed.

Here is what consumers can verify independently versus what the company’s marketing materials state: the official website describes Sugar Harmony Drops as containing “all natural ingredients” and “maximum strength premium vitamins.” The company’s references section cites 32 published studies. What consumers can verify at this stage is whether the product publicly discloses specific per-ingredient amounts per serving — the official website materials reviewed for this report do not list per-ingredient milligram amounts — and whether any published study has tested the finished formula as sold. Publicly available sources reviewed for this report do not indicate one. That distinction shapes every concern addressed below.

Are the Sugar Harmony Drops Ingredients Backed by Research?

The official SugarHarmony website’s references section lists 32 scientific citations corresponding to ingredients associated with the formula. Referenced compounds include Gymnema Sylvestre, Chromium Picolinate, Bitter Melon, Cinnamon Extract, Green Tea Catechins, Astragalus Membranaceus, Grape Seed Extract, Forskolin, Korean Ginseng, Ashwagandha, Capsaicin, GABA, L-Carnitine, African Mango, and additional botanicals and amino acids.

Several of these ingredients have appeared in peer-reviewed research published in journals such as the Journal of Ethnopharmacology, Diabetes Care, American Journal of Clinical Nutrition, and Phytotherapy Research. Gymnema Sylvestre has been studied in relation to glucose metabolism markers in published nutrition research. Chromium Picolinate has been studied in relation to glucose metabolism parameters, though findings vary across study designs and dosages. Cinnamon and Bitter Melon each appear in metabolic health literature with varying degrees of evidence depending on study populations and dosing protocols.

The concern that matters most here isn’t whether these ingredients appear in published research — many of them do. The more relevant question is whether the specific dosages used in those published studies correspond to what Sugar Harmony Drops delivers per serving. The official product page and marketplace listings describe the formula using general terms but do not appear to disclose the specific milligram amount of each individual ingredient per serving.

The presence of scientific references can indicate ingredient-level research interest, but it does not confirm the dose, quality, or real-world outcomes of the finished Sugar Harmony Drops formula unless full per-ingredient amounts and product-level clinical data are publicly available. Without that per-ingredient dosage disclosure, consumers can’t independently map the cited research to the product’s actual per-serving composition.

Does Sugar Harmony Drops Have Clinical Trials as a Finished Product?

This is one of the most common points of confusion in supplement evaluation, and it applies broadly across the dietary supplement category — not just to this product.

A review of publicly available materials on the official website — including the product page, policies, and references — did not identify a published clinical trial evaluating Sugar Harmony Drops as a finished proprietary formula. The 32 scientific references on the product website correspond to studies on individual ingredients tested in isolation under specific research conditions. Those studies examined single compounds at known dosages — they didn’t evaluate the combined multi-ingredient liquid supplement as sold.

Under current federal regulations, dietary supplements are not required to undergo pre-market clinical testing or receive FDA approval before being sold. The FDA does not evaluate supplement efficacy claims prior to market entry. The company’s own website includes the standard regulatory disclaimer that statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumers researching terms such as “Sugar Harmony clinical study,” “SugarHarmony FDA approved,” “Sugar Harmony Drops proven,” or “does Sugar Harmony actually work” should understand that the distinction between ingredient-level research and product-level clinical validation is the key factor in interpreting the company’s scientific references. That’s standard across the supplement industry, but it’s especially important to understand when you’re making a health-related purchasing decision.

SugarHarmony Pricing Structure and the 6-Bottle Fulfillment Process

Publicly listed pricing on the official website includes multiple package formats — including multi-bottle options — with different total pricing and shipping terms. At the time this report was prepared, the site displayed pricing that varied by bottle quantity, with the 6-bottle option listed at $49 per bottle as an example. Other formats are also listed and may change. Because pricing and promotions can be updated at any time, consumers should confirm the current offer and checkout terms directly on the official product page before purchase.

Purchases are processed through ClickBank, which the company identifies as the retailer for this product. Pricing on the official website describes these as one-time purchases.

Consumers can confirm current pricing and availability by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page), as pricing may change at any time.

One area generating specific consumer questions involves the 6-bottle package fulfillment process. Per the company’s published Terms of Service, the 6-bottle offer includes a multi-step fulfillment procedure: only three bottles ship initially. The remaining three require the buyer to scan a QR code included with the shipment, navigate to a secure webpage, submit personal information including full name, email address, and order number, and complete this process within 60 days of the original purchase date.

The published terms state that missing the required request steps or deadline may result in not receiving the remaining bottles under that offer. Consumers considering the 6-bottle package should review the current fulfillment terms directly on the official website before selecting this option.

Sugar Harmony Drops Refund Policy: Requirements and Return Process

The company’s published refund policy describes a 60-day satisfaction guarantee from the date the order is shipped. If you’re unsatisfied within the guarantee period, the company states that you can request a full refund by contacting their support team.

The refund process includes specific requirements worth understanding before purchasing. All bottles must be returned — whether empty, full, or partially full — including any bonus or free bottles received as part of the order. Returns must be shipped to the fulfillment address at 285 Northeast Ave, Tallmadge, OH 44278 with a written note including the order ID, full name, address, email, and phone number.

The buyer is responsible for return shipping costs and must provide a tracking number. According to the published return policy, consumers should contact the support team and receive confirmation from an agent before initiating a return. Failing to do so could result in complications with locating the return and may delay the refund.

Refund processing timelines depend on the buyer’s financial institution. The company’s refund page states that processing may take several business days to appear on financial statements after the return has been received. Refund requests can also be initiated through ClickBank’s self-service billing portal.

Sugar Harmony Drops Marketing Language and Testimonial Context

Official marketing materials describe Sugar Harmony Drops as supporting an active lifestyle, containing maximum strength ingredients, promoting overall well-being, and being crafted with carefully selected natural ingredients. These are general wellness positioning statements consistent with how many dietary supplements are marketed.

Here is what the company states versus what consumers can verify regarding testimonials: the company’s disclaimer section states that testimonials, case studies, and examples are results forwarded by users and are not intended to represent or guarantee that anyone will achieve the same or similar results. The published terms also note that some names and personal identifying information may have been changed to protect privacy.

Testimonials describe individual experiences and do not establish typical outcomes. Consumers should interpret them alongside published disclaimers and the broader evidence limitations described in this report. When evaluating promotional content, look for specific outcome descriptions that include context about duration of use and accompanying lifestyle factors, and weigh those alongside the product’s regulatory context and the ingredient-versus-product research distinction outlined above.

Who Is Behind SugarHarmony?

Marketplace listings on Amazon associate the product with the brand name Syvor, while the official website operates under the name SugarHarmony Research. Payments are processed through ClickBank (Click Sales Inc.), and the fulfillment address is listed in Tallmadge, Ohio.

The official website does not prominently disclose specific details about the manufacturing facility, including GMP (Good Manufacturing Practices) certification status, the identity of the contract manufacturer, or third-party testing protocols. These are details that some consumers consider important when evaluating supplement quality and consistency.

Consumers who prioritize manufacturing transparency may want to contact the company directly at support@getsugarharmony.com to request additional information about production standards, ingredient sourcing, and quality assurance procedures before making a purchasing decision.

Verification Steps Consumers Often Use Before Purchasing

Confirm whether individual ingredient dosages are disclosed. Full-disclosure labeling allows you and your healthcare provider to compare per-serving amounts against published research. When specific amounts aren’t listed, consider contacting the manufacturer directly.

Understand the difference between ingredient research and finished-product research. Many supplements reference published studies on individual compounds. Fewer have been evaluated as finished multi-ingredient formulations. Knowing which type of evidence you’re looking at helps set realistic expectations.

Read the full terms of service before selecting a pricing package. Important details about fulfillment procedures, refund requirements, and purchase conditions are often found in the terms pages rather than on the main product page.

Verify that promotional content originates from official brand channels. Third-party advertising and intermediary pages may not reflect the company’s current terms, pricing, or product details. Confirm information directly on the official website.

Consult a qualified healthcare provider. This is especially important if you’re taking prescription medications or managing an existing health condition. A clinician familiar with your personal medical history is the most reliable resource for evaluating whether any supplement is appropriate for your situation.

Liquid Supplement Format Considerations in 2026

Marketed in a liquid drop format, this product represents one of several delivery methods used across the dietary supplement category. Liquid formulations are sometimes marketed with claims about absorption advantages compared to capsule or tablet formats. The bioavailability of any supplement depends on multiple factors, including the specific compounds involved, the formulation excipients, individual digestive health, and whether the product is taken with food.

Consumers evaluating liquid supplements should apply the same evidence standards they would apply to any other supplement format: look for per-ingredient dosage transparency, check for published research on the finished formulation where available, and consult a healthcare provider about whether the delivery format is relevant to their specific health considerations.

Who Might Consider Sugar Harmony Drops — and Who Might Not

Based on the product’s positioning and publicly available information, Sugar Harmony Drops may appeal to adults who prefer liquid supplement formats and who are exploring natural ingredient-based options as one component of a broader wellness approach that includes balanced nutrition, regular physical activity, and professional healthcare guidance.

It may be less suited for consumers who require transparent individual ingredient dosing to make clinical comparisons against published research, those who need medically validated interventions for a diagnosed condition, or anyone expecting significant changes from a single supplement without accompanying lifestyle modifications.

As with all dietary supplements, individual outcomes depend on personal health factors, and the FDA does not evaluate supplement efficacy claims before products reach the market.

Consumer Questions About Sugar Harmony Drops

Is SugarHarmony a legitimate product?

As a commercially available dietary supplement, it’s sold through the official website getsugarharmony.com and processed through ClickBank. The product is also listed on Amazon under the Syvor brand name. It references ingredients that appear in published peer-reviewed research at the ingredient level. The product has not been evaluated by the FDA, which is standard for dietary supplements under current federal regulations. Consumers should evaluate the product based on the information and considerations outlined in this report.

What are the most common concerns about Sugar Harmony Drops?

Consumer search patterns indicate questions about ingredient dosage transparency, the absence of finished-product clinical trials, the 6-bottle fulfillment process, refund timelines, and the distinction between ingredient-level research and product-level evidence. Each of these concerns is addressed in the sections above.

Does the product disclose individual ingredient amounts?

Publicly available product labeling and the official website describe the formula as containing all-natural ingredients and maximum strength premium vitamins. Specific milligram amounts per individual ingredient per serving do not appear to be publicly disclosed. Consumers may contact the manufacturer for additional details.

Is Sugar Harmony Drops FDA approved?

This product is a dietary supplement and does not require FDA approval under current federal regulations. The FDA does not evaluate supplement efficacy claims prior to market entry. The company’s website includes the standard FDA disclaimer.

How does the refund process work?

The company publishes a 60-day satisfaction guarantee from the shipping date. Refund requests require returning all bottles to the Tallmadge, Ohio fulfillment address with order details included. The buyer covers return shipping and must contact support before initiating the return. Processing timelines depend on the buyer’s financial institution. Requests may also be initiated through ClickBank’s billing portal.

What happens if I don’t complete the 6-bottle QR code process?

Per the company’s Terms of Service, missing the required steps or the 60-day deadline may result in not receiving the remaining three bottles under that offer. Consumers considering the 6-bottle package should review these terms carefully before purchasing.

Are testimonials on the website representative of typical results?

Published disclaimer language on the official website states that testimonials and case studies are results forwarded by users and are not intended to represent or guarantee similar outcomes. Some names and identifying information may have been changed. Consumers should evaluate testimonials alongside published disclaimers and the regulatory context described in this report.

Where is Sugar Harmony Drops manufactured?

The fulfillment address is in Tallmadge, Ohio. Marketplace listings associate the product with the Syvor brand. The official website does not prominently disclose specific manufacturing facility details or GMP certification status. Consumers may contact support for additional manufacturing information.

Can this product replace medical treatment for blood sugar management?

Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. This product should not be used as a replacement for professional medical treatment. Consumers managing blood sugar-related health conditions should consult their healthcare provider before starting any supplement and should continue any prescribed treatment regimen.

How does Sugar Harmony Drops compare to other supplements in this category?

This evaluation focuses specifically on Sugar Harmony Drops and does not provide comparative rankings. Consumers interested in comparative analysis should evaluate each product using the same verification framework: ingredient dosage transparency, published research type, manufacturing disclosure, and refund terms.

What’s the best way to verify claims independently?

Request per-ingredient dosage information from the manufacturer. Cross-reference disclosed amounts against dosages used in the cited published studies. Confirm current pricing, fulfillment terms, and refund policies on the official website. Consult a healthcare provider familiar with your medical history before purchasing any dietary supplement.

Additional Consumer Research

Independent research across multiple consumer publications, peer-reviewed sources, and regulatory guidance from the FDA may provide broader perspective on liquid dietary supplements, metabolic wellness ingredient research, and supplement evaluation frameworks. Evaluating multiple sources is recommended before making any purchasing decision.

Summary of Key Considerations

Consumer concerns around Sugar Harmony Drops center on ingredient dosage transparency, the distinction between ingredient-level and product-level research, the multi-step 6-bottle fulfillment process, and refund procedure requirements. The product references 32 published studies on individual ingredients, but publicly available sources do not indicate a clinical study evaluating the finished formula. Individual ingredient amounts per serving do not appear to be publicly disclosed. The company provides a 60-day refund guarantee processed through ClickBank, with specific return requirements outlined in their published policies.

Here is a final summary of what the company states versus what consumers can independently verify before purchasing: the company states the formula contains maximum strength natural ingredients backed by research. What consumers can verify is that the cited research pertains to individual ingredients studied in isolation, that per-ingredient dosages are not publicly disclosed for the finished product, and that the refund and fulfillment processes include specific procedural requirements detailed in the company’s published terms. Reviewing those terms directly is the most useful step any consumer can take before deciding.

Complete product details, current pricing, and published terms are available by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page).

Contact Information

Company: SugarHarmony Research

Return Address: 285 Northeast Ave, Tallmadge, OH 44278

Email: support@getsugarharmony.com

Support: (323) 388-4197

Website: getsugarharmony.com

Retailer (per website disclosure): Click Sales Inc., 1444 S. Entertainment Ave., Suite 410, Boise, ID 83709

Self-Service Billing Support: Available through ClickBank’s order support portal

ClickBank Order Support: https://www.clkbank.com/?

US: 1-800-390-6035

INT: 1-208-345-4245

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Health and wellness concerns should be discussed with a qualified healthcare provider who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, bonus offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms on the official website and through ClickBank order support before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. Click Sales Inc. (ClickBank) serves as the retailer for this product, as identified on the company’s website. ClickBank’s role as retailer does not constitute an endorsement, approval, or review of this product or any claim, statement, or opinion used in its promotion. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: support@getsugarharmony.com
Support: (323) 388-4197

Purisaki Berberine Patches Claims Evaluated: 2026 Consumer Report on Transdermal Berberine Delivery, Patch Absorption Science, and What Buyers Should Verify




Purisaki Berberine Patches Claims Evaluated: 2026 Consumer Report on Transdermal Berberine Delivery, Patch Absorption Science, and What Buyers Should Verify

An informational 2026 consumer report examining Purisaki Berberine Patches’ transdermal delivery claims, ingredient research context, pricing structure, and what to confirm before purchasing

Wayne, NJ, March 04, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an independent informational report and does not provide medical advice or product recommendations. All product statements are presented as described by the company and should be verified on the official website. In this report, terms like “effective” or “works” refer only to marketing language and do not indicate clinical proof of the finished product.

Consumer search interest in berberine patches and transdermal supplement formats has continued to grow heading into 2026 — particularly among adults exploring non-pill alternatives to traditional capsules and those curious whether patch-based delivery changes how botanical compounds like berberine interact with the body.

Purisaki Berberine Patches have become one of the more visible products in this space. The company markets the patch as a plant-based transdermal wellness product, positioning it around the idea that berberine delivered through the skin may bypass the digestive limitations that have been well-documented in oral berberine research. That premise is central to the product’s marketing — but it also raises questions that deserve straightforward answers.

Is transdermal berberine delivery actually supported by published research? How do the weight management claims on the Purisaki product page hold up when you compare them to what the scientific literature says about berberine as a compound? And does a consumer adhesive patch deliver enough active ingredient to be meaningful?

This report walks through what the company states, what ingredient-level research supports under controlled conditions, and where the gaps sit between marketing language and product-level evidence. It doesn’t recommend for or against the product — it gives you the information you’d want before deciding for yourself.

Current product details, pricing, and terms can be confirmed by viewing the current Purisaki Berberine Patches offer (official Purisaki page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

What Are Purisaki Berberine Patches

Purisaki Berberine Patches are transdermal supplement patches marketed as a plant-based formula for daily wellness and weight management support. The company describes them as an adhesive patch applied to the skin for an eight-hour wear period, positioned as a convenient alternative to traditional capsules and tablets.

The brand is operated by UAB BeWell EU, registered at Gynėjų St. 4-333, LT-01109 Vilnius, Lithuania (company registration number 305788600). Per the published Terms of Service, goods are manufactured and shipped from fulfillment centers that may be located outside the company’s office address, with the designated returns center at QuickBox Fulfillment, 415 Hamburg Turnpike, Building B, 07470 Wayne, NJ, United States.

Publicly available product information describes a multi-ingredient patch containing berberine extract, fucoxanthin extract, pomegranate oil (punicic acid extract), green tea extract, African mango extract, vitamins C, B1, and B3, plus additional natural ingredients. The delivery system is described as a multi-layer design featuring a breathable comfort layer, biodegradable protective outer layer, and a berberine release core layer for controlled delivery.

A 4.3-star average from over 8,658 reviews is displayed on the website. Individual ingredient concentrations per patch are not disclosed in publicly available materials. The standard FDA disclaimer on the site confirms that products and claims have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Berberine Research Context: What Published Studies Examine vs. What Purisaki Claims

Berberine is a naturally occurring alkaloid found in plants including barberry, goldenseal, and Oregon grape. It’s one of the more thoroughly studied botanical compounds in the metabolic health space, and that research is worth understanding on its own terms before connecting it to any specific product.

A 2020 meta-analysis published in Clinical Nutrition ESPEN, covering 12 randomized controlled trials, found that oral berberine supplementation was associated with moderate but statistically significant reductions in body weight, BMI, waist circumference, and C-reactive protein in participants with metabolic disorders. A separate dose-response meta-analysis in Complementary Therapies in Clinical Practice reported significant influence on BMI and waist circumference across 10 studies. Review literature in Frontiers in Pharmacology concluded that berberine alone could reduce key metabolic markers including triglycerides, cholesterol, fasting glucose, and insulin resistance through AMPK pathway activation.

That’s real science on a real compound. But here’s where it gets important for anyone researching Purisaki specifically.

Every study referenced above examined oral berberine at disclosed dosages — typically 500 mg to 1,500 mg daily. Purisaki delivers berberine through a transdermal patch, which is a fundamentally different delivery mechanism. The published research on transdermal berberine in humans is substantially more limited. A 2018 pharmacokinetic study in PLOS ONE examined transdermal berberine formulations in animal models using pharmaceutical-grade cream bases. A 2024 study in Analytical and Bioanalytical Chemistry demonstrated that berberine loaded in chitosan microneedle arrays could permeate to both epidermis and dermis layers — but that examined microneedle technology, not a consumer adhesive patch.

Connecting the body of oral berberine research directly to a transdermal patch product would require published evidence showing comparable bioavailability through the skin. The stratum corneum — the skin’s outermost layer — acts as a selective barrier, and not all molecules pass through it with equal efficiency. That distinction matters when you’re comparing what’s been studied to what’s being marketed.

Marketing Claims: What’s Stated vs. What Can Be Verified

The official Purisaki product page includes marketing language such as “Lose 12+ lbs Per Month Easily” and “Feel The Change In 1 Week,” but independent clinical trials on the finished Purisaki patch product do not appear in the published literature. Consumers can confirm current claim language and terms on the official page.

For context, published meta-analyses on oral berberine — at known dosages, through oral delivery — found average weight reductions of approximately 2 kg (about 4.5 lbs) across study durations that varied from weeks to months. That’s substantially less than the 12-pound monthly figure in Purisaki’s marketing, and those studies examined oral supplementation rather than transdermal patch delivery.

The site’s own FAQ section separately states “consistent daily use for at least 90 days” is suggested for best results, which is more consistent with published berberine research timelines than the “1 week” marketing language on the main product page.

Additional claims describe berberine as helping “flip your metabolism from storage mode to burn mode” and reference “Scientifically Studied Plants” with “Ingredients proven to help control hunger and shrink waist size in days.” While individual ingredients have been studied in published research, the word “proven” in that context overstates the evidence: ingredient-level studies don’t validate a multi-ingredient patch formula, oral results don’t automatically apply to transdermal delivery, and “in days” doesn’t align with timelines in the published berberine literature.

This does not establish how the finished product performs. It clarifies what the published evidence does and does not confirm for this specific delivery format.

Transdermal Delivery: What’s Established and What’s Uncertain

Transdermal delivery is well-established in pharmaceutical applications. Nicotine patches, hormone replacement patches, and certain pain management patches all have extensive clinical validation. Those products are regulated and clinically tested in ways that differ from consumer botanical wellness patches, so their performance data cannot be used to infer outcomes for berberine patches. For botanical compounds like berberine, transdermal delivery through consumer adhesive patches represents a newer and less-studied application.

The practical question is whether berberine — a relatively large botanical molecule — can be absorbed through the skin at meaningful dosages via a standard adhesive patch. Published research exploring transdermal berberine has primarily used advanced delivery technologies like pharmaceutical-grade cream bases with penetration enhancers or microneedle arrays that create temporary micro-channels in the skin. Those are distinct from a consumer wellness patch.

Independent bioavailability data on the finished Purisaki patch product does not appear in the published literature. Without that data, there’s no way to independently confirm whether the patch delivers berberine at concentrations comparable to the oral dosages used in research studies. This is perhaps the most important gap for consumers to understand when assessing the product’s marketing claims.

What Consumers Are Searching — and What the Evidence Actually Addresses

People researching terms like “berberine patches,” “do berberine patches work,” “Purisaki berberine patch effectiveness,” “transdermal berberine delivery,” or “Purisaki weight loss results” are generally trying to answer the same core question: does this format deliver berberine in a way that produces the metabolic effects documented in published research?

The honest answer, based on currently available evidence, is that the published research primarily examines oral berberine at disclosed dosages between 500 mg and 1,500 mg daily. Transdermal berberine delivery through consumer adhesive patches has not been validated through independent clinical trials with published bioavailability data. That doesn’t rule out the possibility of benefit — it means the specific evidence gap between oral research and transdermal patch delivery hasn’t been closed by publicly available data.

Purisaki Berberine Patches Pricing

Pricing displayed on the official website at the time of writing ranged from approximately $35 to $70 depending on package selection, with shipping listed separately at $4.95. The site prominently displays discount language and states that special pricing may expire. A subscription option with recurring monthly billing is also available. Pricing, discounts, and package options can change and should be verified directly on the official site.

Consumers can confirm current pricing and availability by viewing the current Purisaki Berberine Patches offer (official Purisaki page), as pricing may change at any time.

Refund Policy and 60-Day Return Window

The published return policy provides a 60-day window from delivery. Returns within the first 14 days qualify for a full refund, while those initiated after 14 days but within the 60-day window may incur additional fees. A Return Merchandise Authorization (RMA) code from customer support is required before sending products back, and returns are accepted only at the designated fulfillment center address — not the company’s registered office.

Shipping costs are not refundable, and consumers cover return shipping. The company states refunds are processed within 14 days of receiving returned goods, issued to the original payment method. Actual appearance depends on the buyer’s financial institution. Complete return terms should be reviewed directly on the official website.

Testimonials: What’s Displayed and What Buyers Should Know

The website displays testimonials that describe outcomes including weight loss of 7, 15, and 16 pounds, reduced cravings, and improved energy, labeled “Verified Customer.” These outcomes have not been independently verified.

Section 11.2 of the published Terms of Service states that “all testimonials and/or comments displayed on the Website might have fictional names and associative pictures.” This means the names and images associated with testimonials may not represent actual customers. Section 11.4 separately notes the company reserves the right to moderate or decline to publish reviews not meeting content guidelines. The site’s FDA disclaimer also confirms that individual results may vary. Readers should factor all of these disclosures into how they interpret testimonial content.

Consumer Verification Checklist

Ask about per-patch ingredient dosages. Berberine amounts per patch are not publicly disclosed. If dosing matters to your decision-making — and it should, given that published research uses specific dosage ranges — contact the manufacturer directly.

Understand the oral-to-transdermal evidence gap. Published berberine studies examine oral supplementation. Transdermal delivery through consumer adhesive patches is a less-studied format with limited independent bioavailability data.

Check the Terms of Service for testimonial disclosures. Section 11.2 states names and images may be fictional. That’s worth reading before forming expectations based on testimonial content.

Confirm refund conditions before ordering. The 60-day window has different terms before and after the 14-day mark. An RMA code is required, and shipping costs are non-refundable.

Note the shipping origin and timeline. Per the Terms of Service, most goods ship from China. U.S. delivery estimates are 8-12 business days, and import duties may apply depending on local laws.

Consult a healthcare provider first. This applies especially for adults taking medications, managing chronic conditions, or with sensitive skin. The Terms of Service explicitly state goods “are not for sensitive skin” and recommend a 24-hour patch test before first use.

Who Might Be Researching This Product in 2026

Based on the published positioning, Purisaki Berberine Patches appear to target adults who prefer non-pill supplement formats and are interested in berberine as one component of a broader wellness approach that includes balanced nutrition and physical activity.

Consumers who require transparent per-ingredient dosing for clinical comparison, those seeking a format backed by established bioavailability data, or individuals expecting significant weight loss from a single product without lifestyle changes may find the current evidence base insufficient for their decision-making.

As stated in the standard FDA disclaimer displayed on the company’s website, the product’s statements have not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumer Questions About Purisaki Berberine Patches

How do berberine patches differ from capsules?

Patches are designed to deliver berberine through the skin, bypassing digestive metabolism. The theoretical advantage is avoiding the well-documented bioavailability challenges of oral berberine. However, clinical evidence specifically validating consumer adhesive patches for berberine delivery is more limited than the oral research base, and the two formats haven’t been directly compared in published studies.

Does the FDA regulate Purisaki Berberine Patches?

Dietary supplements do not require FDA approval before being sold under current federal regulations. The FDA disclaimer on the Purisaki website confirms this directly.

How much berberine does each patch contain?

Specific amounts per patch are not disclosed in publicly available product materials. Published oral berberine studies showing metabolic effects typically use 500 mg to 1,500 mg daily — a useful reference point when comparing any berberine product to published research.

Can the weight loss claims be independently verified?

The marketing language states consumers can “Lose 12+ lbs Per Month Easily.” Published meta-analyses on oral berberine found average reductions of approximately 2 kg across study durations at known oral dosages. Independent clinical testing of the finished Purisaki patch product does not appear in the published literature.

Are the website testimonials independently verified?

The Terms of Service (Section 11.2) disclose that testimonial names and images may be fictional. The testimonial outcomes described on the site have not been independently verified.

What is the refund process?

A 60-day return window applies from delivery. Full refunds apply to returns within 14 days; later returns may incur fees. An RMA code is required from customer support, shipping costs are non-refundable, and processing takes up to 14 days after goods are received.

Where is the product manufactured and shipped from?

Per the Terms of Service, most goods are manufactured and delivered from China. The brand’s operating company is registered in Vilnius, Lithuania, with returns processed through a fulfillment center in Wayne, New Jersey.

Is this product safe for sensitive skin?

The Terms of Service explicitly state that goods “are not for sensitive skin” and recommend a 24-hour test before first use. Anyone with a skin condition should consult a healthcare provider before using transdermal patch products.

How long does the company recommend using the patches?

The FAQ section states that consistent daily use for at least 90 days is suggested for best results. Published oral berberine research examines intervention periods ranging from several weeks to several months, generally consistent with that timeline.

Is there a subscription, and can I cancel?

Yes, a subscription option exists with recurring monthly billing. Cancellation is available anytime through customer support. Whether the current or next month’s shipment is affected depends on whether the order has already been dispatched.

Additional Consumer Research

Independent research across multiple peer-reviewed sources and healthcare provider resources may provide broader perspective on berberine supplementation, transdermal delivery science, and weight management products. Consulting multiple sources is recommended before making any purchasing decision.

Summary of Key Considerations

As a transdermal supplement product, Purisaki Berberine Patches position themselves around berberine’s published metabolic research while using a patch delivery format that is less studied than oral supplementation. The product contains berberine and additional botanical ingredients, though individual amounts per patch are not publicly disclosed.

Published berberine research — primarily examining oral supplementation at known dosages — has found moderate effects on metabolic markers including body weight, BMI, and waist circumference. Independent clinical testing of the finished Purisaki patch product does not appear in the published literature, and the gap between oral berberine research and transdermal patch delivery remains an important consideration for consumers doing their own research.

The marketing claim of “Lose 12+ lbs Per Month” significantly exceeds the weight loss figures reported in published oral berberine meta-analyses. Testimonials on the website are accompanied by a Terms of Service disclosure stating names and images may be fictional, and outcomes described have not been independently verified.

Complete product details, current pricing, and published terms are available by viewing the current Purisaki Berberine Patches offer (official Purisaki page).

Contact Information

Brand: Purisaki Berberine Patches

Operating Company: UAB BeWell EU

Registered Address: Gynėjų St. 4-333, LT-01109 Vilnius, Lithuania

Company Registration No.: 305788600

Returns Address: Returns – QuickBox Fulfillment, 415 Hamburg Turnpike, Building B, 07470 Wayne, NJ, United States

Email: support@purisaki.com

Phone (US): +1 (850) 389-0125

Phone (UK): +442080891401

Phone (DE): +498004009820

Website: https://trypurisaki.com/

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Weight management concerns should be discussed with a qualified healthcare provider familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: support@purisaki.com
Phone (US): +1 (850) 389-0125
Phone (UK): +442080891401
Phone (DE): +498004009820

Medline Inc. announces pricing of secondary offering of class A common stock




Medline Inc. announces pricing of secondary offering of class A common stock

NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock. The offering is expected to close on March 10, 2026, subject to customary closing conditions.

Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.

The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medline

Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

Contacts:

Investor Relations:
Karen King
Global Head Investor Relations

Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com

Source: Medline Inc.

HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance




HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance

HITRUST r2 Certification validates HealthRecon Connect’s commitment to strong cybersecurity and protecting sensitive healthcare data

SOUTHLAKE, Texas, March 04, 2026 (GLOBE NEWSWIRE) — HealthRecon Connect, a leading provider of technology-enabled Revenue Cycle Management solutions to U.S. healthcare organizations, today announced that its Revenue Cycle Management platform and associated solutions — including Analytics & Dashboards, CDM Solution (Collections & Denial Management), CRD Solution (Credentialing & Payor Enrollment), CSE Solution (Claims Status Enquiry), Data Exchange Interface, EZCIP Solution (Client Information Portal), HRC Billing System (HBS), K1 Patient Pay Platform, and OneHRC Platform, have earned certified status by HITRUST for information security.

HITRUST r2 Certification demonstrates that HealthRecon Connect’s certified systems have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. This achievement places HealthRecon Connect in an elite group of organizations worldwide that have earned this certification.

By incorporating federal and state regulations, global standards, and industry frameworks into a unified and scalable control framework, the HITRUST Assurance Program helps organizations address complex security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“Organizations like ours operate in an environment that demands constant vigilance in addressing current and emerging threats, alongside complex compliance, information protection, and privacy requirements,” said Denver Fernando, CEO of HealthRecon Connect. “Achieving HITRUST r2 Certification demonstrates our disciplined approach to cybersecurity, governance, and operational controls, and reinforces our commitment to protecting our clients’ data as we continue to scale and innovate.”

“HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

About HealthRecon Connect
HealthRecon Connect provides technology-enabled Revenue Cycle Management solutions to U.S. healthcare providers. Leveraging over 30 years of deep domain expertise, alongside machine learning, AI, advanced analytics, and automated workflows, the company helps improve cash flow, enhance operational efficiency, and deliver measurable outcomes for its clients.

For more information, please write to info@healthreconconnect.com or visit www.healthreconconnect.com

Medline Inc. announces pricing of secondary offering of class A common stock




Medline Inc. announces pricing of secondary offering of class A common stock

NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock. The offering is expected to close on March 10, 2026, subject to customary closing conditions.

Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.

The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medline

Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

Contacts:

Investor Relations:
Karen King
Global Head Investor Relations

Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com

Source: Medline Inc.

HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance




HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance

HITRUST r2 Certification validates HealthRecon Connect’s commitment to strong cybersecurity and protecting sensitive healthcare data

SOUTHLAKE, Texas, March 04, 2026 (GLOBE NEWSWIRE) — HealthRecon Connect, a leading provider of technology-enabled Revenue Cycle Management solutions to U.S. healthcare organizations, today announced that its Revenue Cycle Management platform and associated solutions — including Analytics & Dashboards, CDM Solution (Collections & Denial Management), CRD Solution (Credentialing & Payor Enrollment), CSE Solution (Claims Status Enquiry), Data Exchange Interface, EZCIP Solution (Client Information Portal), HRC Billing System (HBS), K1 Patient Pay Platform, and OneHRC Platform, have earned certified status by HITRUST for information security.

HITRUST r2 Certification demonstrates that HealthRecon Connect’s certified systems have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. This achievement places HealthRecon Connect in an elite group of organizations worldwide that have earned this certification.

By incorporating federal and state regulations, global standards, and industry frameworks into a unified and scalable control framework, the HITRUST Assurance Program helps organizations address complex security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“Organizations like ours operate in an environment that demands constant vigilance in addressing current and emerging threats, alongside complex compliance, information protection, and privacy requirements,” said Denver Fernando, CEO of HealthRecon Connect. “Achieving HITRUST r2 Certification demonstrates our disciplined approach to cybersecurity, governance, and operational controls, and reinforces our commitment to protecting our clients’ data as we continue to scale and innovate.”

“HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

About HealthRecon Connect
HealthRecon Connect provides technology-enabled Revenue Cycle Management solutions to U.S. healthcare providers. Leveraging over 30 years of deep domain expertise, alongside machine learning, AI, advanced analytics, and automated workflows, the company helps improve cash flow, enhance operational efficiency, and deliver measurable outcomes for its clients.

For more information, please write to info@healthreconconnect.com or visit www.healthreconconnect.com

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome




The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) —  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies that demonstrate, for the first time, the potential for disease modification in people living with Dravet syndrome. These data showed substantial and durable reductions in seizures and improvements across multiple measures of cognition and behavior that began in the Phase 1/2a treatment period and continued through three additional years of treatment in the OLEs. The effects were shown in people treated with zorevunersen on top of standard of care anti-seizure medicines (ASMs).

Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) in which people experience severe and recurrent seizures and a plateauing in their neurodevelopment around the age of two. Over time, children with Dravet syndrome fall further and further behind their neurotypical peers in their ability to achieve developmental milestones. There are currently no approved disease-modifying medicines to treat Dravet syndrome.

“These data mark a potential turning point in the treatment of Dravet syndrome,” said Helen Cross, MB ChB, Ph.D., corresponding author of the NEJM publication and The Prince of Wales’s Chair of Childhood Epilepsy and Director of University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital. “While reducing seizures is still critical, the improvements in cognition, behavior and quality of life seen in these studies suggest we may be changing the course of the disease and therefore the lives of patients and their families.”

“Dravet syndrome arrives without warning for families, just as it did for our family more than 25 years ago when my son began having seizures,” said Mary Anne Meskis, Chief Executive Officer of the Dravet Syndrome Foundation. “While awareness, diagnosis and medical care have advanced significantly over the years, the realities of Dravet syndrome remain severe and life-altering for patients and their families. A treatment that could help someone like my son dress himself independently or better communicate with his parents would profoundly change the cadence and quality of our everyday lives.”

Efficacy Results
The Phase 1/2a studies evaluated single and multiple doses of zorevunersen up to 70 mg with a primary endpoint of safety. Change in major motor seizure frequency was assessed as a secondary endpoint. Substantial reductions in seizures were observed among zorevunersen-treated patients in the Phase 1/2a studies and continued through three years of treatment in the OLEs. The most substantial reductions in seizure frequency were observed among patients treated with initial doses of 70 mg in the Phase 1/2a studies.

Changes in neurodevelopment, functioning, clinical status and quality of life for all patients were assessed as additional endpoints in the OLEs using standard clinical assessments. Improvements in communication, motor skills, socialization, daily living and quality of life continued through three additional years of treatment.

Summary of Safety Data
Zorevunersen has been generally well tolerated across the Phase 1/2a and OLE studies. Eighty-one patients received at least one dose of zorevunersen and were evaluated for safety, and more than 800 doses have been administered across these studies to date. The most common treatment-related adverse event was cerebrospinal fluid (CSF) protein elevations with a higher incidence observed in the OLE studies (44%, n=33/75). No related clinical manifestations have been observed, although one patient discontinued treatment due to elevated CSF protein levels. All serious adverse events were assessed to be unrelated to zorevunersen except in one patient who experienced suspected unexpected serious adverse reactions (SUSARs).

“The discovery of the genetic cause of Dravet syndrome 25 years ago changed how researchers thought about the disease and how to treat it,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “By targeting the underlying genetic cause of the disease, zorevunersen has the potential to be the first disease-modifying medicine for the treatment of Dravet syndrome. We look forward to the results of our Phase 3 EMPEROR study expected in mid-2027.”

“This publication in NEJM demonstrates an appreciation of the severity of Dravet syndrome and the potential of this novel approach to transform the way the disease is treated,” said Katherine Dawson, M.D., Head of Therapeutics Development Unit at Biogen. “For more than 10 years Biogen has been advancing cutting-edge research to address some of the most rare, devastating and neglected diseases, and we are proud to partner with Stoke on this first-of-its-kind investigational drug.”

The full publication titled, “Zorevunersen in Children and Adolescents with Dravet Syndrome,” appears in the March 5 issue of The New England Journal of Medicine.
  
About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. Even when treated with the best available anti-seizure medicines (ASMs), up to 57 percent of patients with Dravet syndrome do not achieve ≥50 percent reduction in seizure frequency. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP; up to 20 percent of children and adolescents with Dravet syndrome die before adulthood due to SUDEP, prolonged seizures, seizure-related accidents or infections ¹. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan ². There are no approved disease-modifying therapies for people living with Dravet syndrome.

About Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.

About the Phase 1/2a and Open-Label Extension Studies of Zorevunersen
Two Phase 1/2a open-label, multicenter studies were conducted and evaluated the effects of zorevunersen in patients with highly refractory Dravet syndrome ages 2 to 18 years (N=81). Primary endpoints were the safety profile, plasma pharmacokinetics (PK) and exposure in cerebrospinal fluid (CSF) of single and multiple doses of zorevunersen. Secondary endpoints included percentage change from baseline in major motor seizure frequency, overall clinical status (a measure of patients’ overall functioning) and quality of life. The ADMIRAL Phase 1/2a study included an exploratory endpoint to evaluate changes in neurodevelopmental status (cognition & behavior) as measured by Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). The Phase 1/2a studies were completed in November 2023.

Following treatment in the Phase 1/2a studies, eligible patients continued treatment with zorevunersen every four months in one of two OLEs. There was at least a 6-month gap between the last dose administered in the Phase 1/2a studies and the first dose administered in the OLEs. The primary endpoints are the safety profile of multiple doses of zorevunersen. Secondary endpoints include PK parameters, percentage change from baseline in major motor seizure frequency, change in overall clinical status, and change from baseline in quality of life. Exploratory endpoints include changes in neurodevelopment status as measured by Vineland-3. The OLE studies are ongoing.

About the Phase 3 EMPEROR Study
The Phase 3 EMPEROR Study (NCT06872125) is a global, double-blind, sham-controlled study evaluating the efficacy, safety and tolerability of zorevunersen in children ages 2 to <18 with Dravet syndrome with a confirmed variant in the SCN1A gene not associated with gain-of-function. Stoke expects to complete enrollment of approximately 150 patients in the United States, United Kingdom and Japan in Q2 2026, with a data readout on track for mid-2027 to support the submission of a New Drug Application (NDA) to the FDA. At least 20 additional patients are expected to enroll in Germany, Spain, France and Italy starting in the second quarter of 2026. Participants are randomized 1:1 to receive either zorevunersen via intrathecal administration or a sham comparator for a 52-week treatment period following an 8-week baseline period. Following the completion of the study treatment period, eligible participants will be offered ongoing treatment with zorevunersen as part of an OLE study. The primary endpoint of the study is percent change from baseline in major motor seizure frequency at week 28 in patients receiving zorevunersen as compared to sham. The key secondary endpoints are the durability of effect on major motor seizure frequency and improvements in behavior and cognition as measured by Vineland-3 subdomains, including expressive communication, receptive communication, interpersonal relationships, coping skills and personal skills. Additional endpoints include safety, Clinician Global Impression of Change (CGI-C), Caregiver Global Impression of Change (CaGI-C) and the Bayley Scales of Infant Development (BSID-IV). For more information, visit https://www.emperorstudy.com/.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, LinkedIn, X, YouTube.

Stoke Therapeutics Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the potential benefits, safety and efficacy of zorevunersen; the timing and expected progress of clinical trials, data readouts, regulatory meetings, regulatory decisions and other presentations. Statements including words such as “plan,” “anticipate”, “potential,” “will,” “continue,” “may”, “expect,” or similar words and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause Stoke’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: Stokes ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if collaborators were to breach or terminate their agreements, Stoke would not obtain the anticipated financial or other benefits; the possibility that Stoke and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; Stoke’s ability to protect its intellectual property; Stoke’s ability to fund development activities and achieve development goals into 2028; and the other risks and uncertainties described under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Stoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential clinical effects of zorevunersen; the potential for zorevunersen to improve outcomes for patients with Dravet syndrome; the potential benefits, safety and efficacy of zorevunersen; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of the underlying causes of Dravet syndrome; the anticipated benefits, risks and potential of Biogen’s collaboration arrangements with Stoke Therapeutics; the potential of Biogen’s commercial business and pipeline programs, including zorevunersen; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Biogen Digital Media Disclosure

From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References:

1. Symonds, J. et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879-2891.
2. Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015.

Stoke Media & Investor Contacts:
Susan Willson
Vice President, Corporate Communications
swillson@stoketherapeutics.com
415-509-8202

Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485

Biogen Media Contact:
Madeleine Shin
Public.affairs@biogen.com
+ 1 781 464 3260

Biogen Investor Contact:
Tim Power
IR@biogen.com
+1 781 464 2442

AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER




AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Carlsbad, California, March 04, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) announced today this it has amended an existing loan (the “Loan”) in the principal amount of US$1,600,000 plus accrued and unpaid interest in the amount of US$1,249,500 from an insider of the Company. The Company has been using the Loan proceeds for general corporate purposes.

The Loan, evidenced by a promissory note (the “Note”) bears interest at 9% per annum. The Amendment reduces the interest rate to 4.5% per annum effective January 1, 2026.  If an Event of Default occurs and continues, the outstanding balance of the Note, including all accrued and unpaid interest, will bear interest at a rate of Twelve Percent (12%) per annum, or at the maximum rate of interest under applicable law. The Principal Amount together with interest thereon, was due on the Maturity Date of June 29, 2027.  The parties have agreed to extend the Maturity Date to July 11, 2029. The parties also agreed that upon a Change of Control of the Company, the Maturity Date will be accelerated, and the Note will be due and payable in full, upon written request from the Holder. The Company may prepay the outstanding principal amount and accrued and unpaid interest thereon, in whole or in part, at any time without penalty. The Company’s wholly owned subsidiary, Aurora Spine, Inc., continues its guarantee and security for the obligations of the Company under the Note.

The Loan constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and the policies of the TSX Venture Exchange but is otherwise exempt from the formal valuation and minority approval requirements of MI 61-101. The Company was not in a position to file a material change report more than twenty-one days in advance of the completion of the Loan.

The Loan is subject to certain conditions including, but not limited to, the receipt of all necessary approvals.

Neither the TSX Venture Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accepts responsibility for the adequacy or accuracy of this release.

About Aurora Spine

Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company’s mission is to improve spinal surgery outcomes through simplified, integrated, and cost-effective solutions that advance patient care worldwide.

Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the manner and timing of repayment of the Loan.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Company and Investor Contacts

Aurora Spine Corporation

Trent J. Northcutt
President and Chief Executive Officer
Phone: (760) 424-2004

Chad Clouse
Chief Financial Officer
Phone: (760) 424-2004

Investor Relations
Adam Lowensteiner
Lytham Partners
Phone: (646) 829-9702
Email: asapf@lythampartners.com